PMID- 30762177
OWN - NLM
STAT- MEDLINE
DCOM- 20200224
LR  - 20200309
IS  - 1546-9549 (Electronic)
IS  - 1546-9530 (Linking)
VI  - 16
IP  - 1
DP  - 2019 Feb
TI  - Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart 
      Failure Patients.
PG  - 38-46
LID - 10.1007/s11897-019-0422-3 [doi]
AB  - PURPOSE OF REVIEW: Despite advances in medical therapy, heart failure with 
      reduced ejection fraction (HFrEF) is still a leading cause of mortality, 
      hospitalizations, and healthcare costs. In this review, we describe two novel, 
      implantable devices for the treatment of patients with HFrEF, cardiac 
      contractility modulation (CCM), and baroreflex activation therapy (BAT), and 
      summarize literature regarding these devices from the last 5 years. RECENT 
      FINDINGS: CCM improves quality of life and functional capacity as assessed by the 
      Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, 6-min hall walk 
      test (6MHWT) distance, New York Heart Association (NYHA) functional class, peak 
      oxygen consumption (pVO(2)), heart failure (HF) hospitalizations, and mortality. 
      BAT improves MLHFQ, 6-min walk test distance, NYHA functional class, and HF 
      hospitalizations. Both devices have been shown to be safe. CCM and BAT have been 
      shown to be safe and effective treatment modalities for HFrEF. CCM has been 
      approved for use in Europe and has been implanted in thousands of patients. BAT 
      has also been approved in Europe and continues to show promise in treating 
      patients with HFrEF who fail optimal medical therapy (OMT). At present, both 
      therapies are considered investigational in the USA.
FAU - Mann, James A
AU  - Mann JA
AD  - Division of Cardiovascular Medicine, Wexner Medical Center at The Ohio State 
      University, 473 W. 12th Avenue Suite 200, Columbus, OH, 43210, USA. 
      james.mann@osumc.edu.
FAU - Abraham, William T
AU  - Abraham WT
AD  - Division of Cardiovascular Medicine, Wexner Medical Center at The Ohio State 
      University, 473 W. 12th Avenue Suite 200, Columbus, OH, 43210, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Heart Fail Rep
JT  - Current heart failure reports
JID - 101196487
SB  - IM
MH  - Baroreflex/*physiology
MH  - Electric Stimulation Therapy/*methods
MH  - Heart Failure/*physiopathology/therapy
MH  - Humans
MH  - Myocardial Contraction/*physiology
MH  - *Quality of Life
MH  - Stroke Volume/*physiology
MH  - Ventricular Function, Left/*physiology
OTO - NOTNLM
OT  - Baroreflex activation therapy
OT  - Cardiac contractility modulation
OT  - Device therapy for heart failure with reduced ejection fraction
EDAT- 2019/02/15 06:00
MHDA- 2020/02/25 06:00
CRDT- 2019/02/15 06:00
PHST- 2019/02/15 06:00 [pubmed]
PHST- 2020/02/25 06:00 [medline]
PHST- 2019/02/15 06:00 [entrez]
AID - 10.1007/s11897-019-0422-3 [pii]
AID - 10.1007/s11897-019-0422-3 [doi]
PST - ppublish
SO  - Curr Heart Fail Rep. 2019 Feb;16(1):38-46. doi: 10.1007/s11897-019-0422-3.